Skip to main content

Sorcero

Category: AI in Healthcare

AI-powered medical intelligence platform transforming life sciences decision-making with medically-tuned AI agents Sorcero was founded in 2018. The company is led by Dipanwita Das. Based in Washington, DC, United States. Team size: 75. Total funding raised: $59M. Latest round: Series B, $42.5M, 2024-11, led by NewSpring Growth. Key investors include NewSpring Growth, Leawood Venture Capital, Blu Ventures, Castor Ventures, G20 Ventures, H/L Ventures, Axiom Health.

Founded
2018
Headquarters
Washington, DC, United States
Team size
75
Total funding
$59M

Value proposition

Accelerates drug development and improves patient outcomes through AI-driven insights and data analysis with 300% more insights from existing data, 18x faster insights generation, and 99.8% sensitivity in relevancy detection

Products and solutions

Sorcero Medical™ - Medical Affairs Intelligence, Sorcero Safety™ - AI-powered Literature Monitoring, Sorcero SciComms™ - Scientific Communications, Sorcero MedTech™ - MedTech Intelligence, Medical Insights Management, Intelligent Publication Monitoring, Plain Language Summary, Intelligent Systematic Literature Review

Unique value

Integration of domain-specific life sciences expertise with cutting-edge AI, leveraging proprietary medically-tuned AI agents and the industry's largest pool of scientific data including 43 million biomedical abstracts, 60+ million full-text articles, 1.2 billion smart citation statements, and 263+ million enriched knowledge graph publications

Target customer

Pharmaceutical companies, biotech firms, medical device manufacturers, and healthcare providers

Industries served

Life Sciences, Healthcare, Pharmaceutical, Biotechnology, Medical Devices

Technology advantage

Proprietary NLP and machine learning models trained on specialized medical datasets, enabling precise interpretation of complex healthcare data with six foundational medical AI patents and regulatory compliance (GxP, GVP, GDPR, SOC 2)

How they differentiate

Sorcero differentiates through its medically-tuned AI platform tailored for life sciences, emphasizing regulatory compliance, specialized AI agents for specific tasks, and partnerships with Google Cloud. It focuses on actionable insights from medical data with 92% productivity improvement in evidence generation, whereas competitors like Huma.AI specialize in generative AI for knowledge automation and ZS in broader life sciences consulting.

Main competitors

Huma.AI, OKRA, ZS Associates

Key partnerships

Google Cloud - Partner of the Year 2025 for Healthcare & Life Sciences, Springer Nature, ServiceNow, USDM Life Sciences, Snowflake, NewSpring Capital, Castor Ventures, G20 Ventures, Leawood Venture Capital, Blu Ventures

Notable customers

One-third of the top 30 global pharma companies, 16-20 life sciences firms overall, Medical affairs teams at major pharmaceutical companies

Major milestones

$42.5M Series B led by NewSpring Capital (November 2024), Partnership with Google Cloud for AI-powered medical analytics - Partner of the Year 2025, Launch of AI Agents for life sciences (March 2025), Named #1 on Fast Company's Most Innovative Companies (Small & Mighty, 2024), Named to America's Most Innovative Companies by Fortune (2025), Named to Inc. 5000 list of fastest-growing companies (2025), Acquisition of Axiom Health for MedTech expansion

Growth metrics

75 employees as of 2025 (grew from ~55 to 75 in 2024-2025), $5.9M ARR (2024), serving one-third of top 30 global pharma companies, named to Inc. 5000 list of fastest-growing companies 2025 (#684)

Market positioning

Positioned as a leader in AI-driven medical intelligence for life sciences, targeting medical affairs teams with specialized AI solutions for evidence-based decision-making and personalized healthcare engagement, serving one-third of the top 30 global pharma companies

Geographic focus

Headquartered in Washington, DC, with operations in Cambridge, MA, and expansion efforts across global life sciences markets including recent acquisition of Axiom Health for medical device market expansion

Patents and IP

Six foundational medical AI patents as of 2025

About Dipanwita Das

Award-winning technology entrepreneur and AI innovator with over 12 years of experience at the intersection of analytics, startups, and health data. Previously founded 42 Strategies, managing digital transformation projects for Richard Branson's Virgin United, Al Gore's Climate Reality Project, and Bloomberg Philanthropies. Atlas Corps Fellow and later Board Member who designed the Global Leadership program. Built international public health platforms that transformed global markets and positively impacted billions of lives.

Official website: